There are 2789 resources available
591P - A first-in-human study of FOR46 in men with metastatic castration resistant prostate cancer (mCRPC)
Presenter: Rahul Aggarwal
Session: ePoster Display
592P - Bipolar androgen therapy (BAT) plus olaparib in men with metastatic castration-resistant prostate cancer (mCRPC)
Presenter: Michael Schweizer
Session: ePoster Display
593P - Pain efficacy with radium-223 (Ra-223) in the REASSURE global, prospective, observational study of men with metastatic castration-resistant prostate cancer (mCRPC)
Presenter: Celestia Higano
Session: ePoster Display
594P - Pain efficacy with radium-223 (Ra-223) in patients (pts) with metastatic castration-resistant prostate cancer (mCRPC) in the PARABO observational study
Presenter: Holger Palmedo
Session: ePoster Display
595P - Correlation between genomic alterations and germline mutations in men with metastatic castration-resistant prostate cancer (mCRPC)
Presenter: Casilda Llacer Perez
Session: ePoster Display
596P - Impact of combined lipidomic and genetic aberrations on clinical outcomes in metastatic castration-resistant prostate cancer (mCRPC)
Presenter: Blossom Mak
Session: ePoster Display
597P - A phase I dose-escalation study of LAE001 in patients with metastatic castration-resistant prostate cancer (mCRPC)
Presenter: Dingwei Ye
Session: ePoster Display
598P - A phase Ib study of enzalutamide (Enza) plus CC-115 in men with metastatic castration-resistant prostate cancer (mCRPC)
Presenter: Jimmy Zhao
Session: ePoster Display
599P - A phase I dose-escalation study of LAE001/prednisone plus afuresertib in patients with metastatic castration-resistant prostate cancer (mCRPC) following standard of care (SOC) treatment
Presenter: Alberto Bessudo
Session: ePoster Display
600P - Final results of phase I/II trial of fractionated dose 177Lu-PSMA-617 for metastatic castration-resistant prostate cancer (mCRPC)
Presenter: Scott Tagawa
Session: ePoster Display